Chronic hepatitis-C infection in COVID-19 patients is associated with in-hospital mortality

Table 4 Comparison between Liver enzymes, acute liver injury, and fibrosis score between patients with and without hepatitis C virus for prediction of mortality, n (%)

	ALl patients (n = 1065)				Propensity score matched (n = 81)
	Univariate		Multivariate		Univariate		Multivariate
	Exp (B)	Sig.	Exp (B)	Exp (B)	Sig.	Exp (B)	Sig.	Sig.
AST/ALT	1.1	< 0.001	1.06	< 0.001	1.204	0.221	-	-
Any liver enzyme elevated	1.427	0.002	0.001	0.823	1.204	0.624	-	-
All AST > ALT	1.455	0.001	0.001	0.852	1.204	0.624	-	-
History of cirrhosis	1.368	0.659	-	-	1.95	0.513	-	-
ALI1	1.418	0.015	1.045	0.792	1.132	0.817	-	-
Fib-4 score	1.02	< 0.001	1.022	< 0.001	1.1	0.042	1.1	0.08
HCV	2.224	< 0.001	2.15	< 0.001	3.88	0.001	3.75	0.002

¹Acute liver injury; defined as any of the following criteria: Both aspartate aminotransferase (AST) and alanine aminotransferase (ALT) elevated 2 times above the upper normal; and Limit or any of AST or ALT elevated 2 times above the upper normal level, and at least one of the following: Elevated combined bilirubin, total bilirubin or elevated PT more than 2 times the normal limit. HCV: Hepatitis C virus; ALI: Acute liver injury AST: Aspartate aminotransferase; ALT: Alanine aminotransferase.